Cell-Free Protein Synthesis Patents: Who Leads, Where the Gaps Are 2026
Cell-Free Protein Synthesis and Ribosome Recycling Patents
68.4% concentration. The top 5 assignees account for 54 of the 79 records in scope — a field where claim space sits with a small group rather than being spread thin. Filings reached 11 in 2017, the high point of the series. By 2021 the annual count had fallen to 1, and by 2024 — the most recent year that can be treated as complete given publication lag — it had reached 0, a -100% move over that three-year span. Later years (2025-2026) are still filling in and should not be read as a continued decline.
- 1AMBRX INC13
- 2POST GENOME INST CO LTD12
- 3KANGMA (SHANGHAI) BIOTECH LTD11
- 4THE UNIV OF TOKYO11
- 5GENEFRONTIER CORP7
See the full cell-free protein synthesis — ribosome recycling patent landscape analysis in Eureka
- The complete ranking, not just the top five
- Every IPC branch with its share of the corpus
- The most-cited records, and where claim space is still thin
Common questions about this landscape
Who holds the most patents in cell-free protein synthesis ribosome recycling?
The assignee ranking in this dataset covers 19 companies, with the leading assignee holding 13 of the 79 records in scope — roughly double the count held by the fifth-ranked entrant at 7. The top 5 assignees together account for 68.4% of all records, and the top 10 reach 93.7%, so the field is concentrated rather than fragmented. Anyone doing freedom-to-operate work here can focus review on a short list of names rather than a long tail of filers.
Is patent filing in this field growing or shrinking?
Filing peaked at 11 records in 2017 and has not returned to that level since; by 2021 annual filings had dropped to 1, and by 2024 — the most recent year treatable as complete — the count reached 0, a -100% change over that span. Because publication lags filing by roughly 18 months, the 2025 and 2026 figures in any chart are still filling in and should not be read as evidence the field has stopped. The honest read is a field with a clear historical peak and reduced recent visible filing, not necessarily reduced actual research activity.
What does US9289742B2 actually cover?
US9289742B2, assigned to GeneFrontier Corporation and granted in 2016, covers a method for producing a protein multimer-nucleic acid complex using sequential in vitro translation steps: one nucleic acid encoding a target component is translated first, then a nucleic acid encoding a non-target component of the same multimer is added and translated to complete the complex. This is a specific multimer-display method rather than a broad claim over cell-free synthesis or ribosome recycling generally. Anyone working on multimer-display or complex-assembly workflows via in vitro translation should read the claims closely against this patent.
Disclaimer. This analysis is based on Patsnap Eureka data drawn from a limited snapshot of global patent records and is provided for general information and reference only. Patent data carries inherent limitations — recent filings are under-counted because of publication lag, counts may be on a record or family basis, classification and applicant-name data may contain errors or duplicates, and the underlying search query defines the scope shown — so the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing here is an exhaustive prior-art, novelty, freedom-to-operate or validity search, nor does it constitute legal, financial or professional advice, and it should not be relied upon as such. Verify independently and review with qualified patent and legal professionals before acting on it.
Method: Filing trend and technology composition. Derived from a Patsnap search on Cell-Free Protein Synthesis — Ribosome Recycling Patent Landscape covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish. Every share divides by all records in scope. Data: Patsnap Eureka. See the full landscape report.